Headline
Resources
| Title | Topic | Year | Link | Document | Notes |
|---|---|---|---|---|---|
| Current Protocol for Phase 3 Clinical Trial of NVX-CoV2373 in the U.S. and Mexico | COVID-19 | 2020 | Document
2019nCoV-301 Version 9_Redacted.pdf
(2.09 MB)
|
Updated January 4, 2022 |
|
| Current Protocol for Phase 3 Clinical Trial of NVX-CoV2373 in the U.K. | COVID-19 | 2020 | Document
|
Updated April 5, 2021 |
|
| Current Protocol for Phase 2b Clinical Trial of NVX-CoV2373 in South Africa | COVID-19 | 2020 | Document
|
Updated January 25, 2021 |
| Title | Topic | Year | Link | Document | Notes |
|---|---|---|---|---|---|
| Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial | COVID-19 | 2021 | Disclaimer: Pre-print only and not yet published in peer-reviewed article |
||
| Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial | Seasonal Influenza | 2021 | https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00192-4/fulltext | The Lancet Infectious Diseases, Shinde V., et al |
|
| Safety and Efficacy of the NVX-CoV2373 Covid-19 Vaccine | COVID-19 | 2021 | https://www.nejm.org/doi/full/10.1056/NEJMoa2107659 | New England Journal of Medicine, Heath P.T., et al |
|
| Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant | COVID-19 | 2021 | https://www.nejm.org/doi/full/10.1056/NEJMoa2103055 | New England Journal of Medicine, Shinde V., et al |
|
| SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice | COVID-19 | 2021 | https://www.nature.com/articles/s41467-020-20653-8 | Nature Communications, Tian J.H., et al |
|
| Structural Characterization and Modeling of a Respiratory Syncytial Virus Fusion Glycoprotein Nanoparticle Vaccine in Solution | Respiratory Syncytial Virus | 2020 | https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.0c00986 | Neutron and X-ray scanning reveal structure of a candidate vaccine’s nanoparticles in a more realistic environment. |
|
| Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine | COVID-19 | 2020 | https://www.nejm.org/doi/full/10.1056/NEJMoa2026920?query=featured_coronavirus | New England Journal of Medicine, Keech, Cheryl, et al |
|
| Induction of Cross-reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine | Seasonal Influenza | 2020 | https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1673/5955953 | Clinical Infectious Diseases, Shinde, Vivek, et al |
|
| Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate | COVID-19 | 2020 | https://science.sciencemag.org/content/sci/early/2020/10/19/science.abe1502.full.pdf | ||
| Severe Morbidity and Short- and Mid- to Long-term Mortality in Older Adults Hospitalized with Respiratory Syncytial Virus Infection | Respiratory Syncytial Virus | 2020 | https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaa361/5863549?guestAccessKey=375780c1-c599-4cf9-bc52-1377448b703b | Journal of Infectious Diseases, Shinde, Vivek, et al |
|
| Flexible RSV Prefusogenic Fusion Glycoprotein Exposes Multiple Neutralizing Epitopes that May Collectively Contribute to Protective Immunity | Respiratory Syncytial Virus | 2020 | Document
FlexibleRSVPrefusogenicFusionGlycoprotein.pdf
(904.53 KB)
|
Vaccine, Patel, Nita, et al |
|
| Hemagglutinin from multiple divergent influenza A and B viruses bind to a distinct branched, sialylated poly-LacNAc glycan by surface plasmon resonance | Seasonal Influenza | 2020 | https://www.sciencedirect.com/science/article/pii/S0264410X20310781 | Vaccine, Bruce-Staskal, Pamela J., et al |
|
| First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine | COVID-19 | 2020 | Disclaimer: Pre-print only and not yet published in peer-reviewed article |
||
| Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants | Respiratory Syncytial Virus | 2020 | Document
NEJMoa1908380.pdf
(593.47 KB)
|
New England Journal of Medicine, Madhi S.A., et al |
|
| SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice | COVID-19 | 2020 | Document
SARS-CoV2_rev75-gs_pap_le-29June2020.pdf
(1.14 MB)
|
Disclaimer: Pre-print only and not yet published in peer-reviewed article |
|
| Prediction of serious RSV‐related outcomes in older adults with outpatient RSV respiratory illness during 12 consecutive seasons | Respiratory Syncytial Virus | 2020 | https://onlinelibrary.wiley.com/doi/full/10.1111/irv.12751 | Influenza and Other Respiratory Viruses | Kieke, BA, et al |
|
| Influenza Hemagglutinin Nanoparticle Vaccine Elicits Broadly Neutralizing Antibodies against Structurally Distinct Domains of H3N2 HA | Seasonal Influenza | 2020 | https://pubmed.ncbi.nlm.nih.gov/32098409/ | Vaccine, Portnoff, Alyse, et al |
|
| Severe Morbidity and Mortality Associated with Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults | Respiratory Syncytial Virus | 2018 | Document
ciy991.pdf
(802.04 KB)
|
Bradley Ackerson, Hung Fu Tseng, Lina S. Sy, Zendi Solano, Jeff Slezak, Yi Luo, Christine A. Fischetti, Vivek Shinde |
|
| Why Making a Diagnosis of Respiratory Syncytial Virus Should Matter to Clinicians | Respiratory Syncytial Virus | 2018 | Document
ciy880.pdf
(375.6 KB)
|
Angela R. Branche, MD |
|
| Improved Titers against Influenza Drift Variants with a Nanoparticle Vaccine | Seasonal Influenza | 2018 | https://www.nejm.org/doi/full/10.1056/NEJMc1803554 | New England Journal of Medicine, Shinde, Vivek, et al |
| Title | Topic | Year | Link | Document | Notes |
|---|---|---|---|---|---|
| Accessing Non-Peer-Reviewed Preprint Literature from Various Servers: An Essential Library Resource to Support Vaccine Development During A Global Pandemic | COVID-19 | 2021 | Document
|
During the Covid-19 pandemic, new information has been changing rapidly and there is significant lag time for new manuscripts to become fully published journal articles. Please download the summary and watch the corresponding video.
|
|
| Antigenic Characterization of RSV Pre-fusogenic F Nanoparticle Vaccine, Pre-F, and Post-F Proteins against a Broad Range of Neutralizing Monoclonal Antibodies and Epitope Responses in Cotton Rats | Respiratory Syncytial Virus | 2018 | Document
Nita_RSV_2018_Poster_Final.pdf
(332.05 KB)
|
11th International Respiratory Syncytial Virus Symposium |
|
| Binding Kinetics of RSV Pre-fusogenic F Nanoparticle Vaccine to Palivizumab and Serum Polyclonal Antibody | Respiratory Syncytial Virus | 2018 | Document
HL_RSV_2018_Poster_Final.pdf
(296.94 KB)
|
11th International Respiratory Syncytial Virus Symposium |
|
| Feasibility Evaluation of Blow Fill Seal Process and Compatibility with Aluminum Phosphate Adjuvanted Recombinant RSV F Nanoparticle Vaccine | Respiratory Syncytial Virus | 2018 | Document
YHLin_RSV_2018_Poster_FINAL.pdf
(619.27 KB)
|
11th International Respiratory Syncytial Virus Symposium |
|
| In-depth Analytical Characterization and Structural Modeling of Novavax RSV F Nanoparticle Vaccine | Respiratory Syncytial Virus | 2018 | Document
|
11th International Respiratory Syncytial Virus Symposium |
|
| Respiratory Syncytial Virus (RSV) Pre-fusogenic F Nanoparticle Vaccine Compared to Pre-fusion F and Post-fusion F Proteins | Respiratory Syncytial Virus | 2018 | Document
Smith_RSV_2018_Poster_Final.pdf
(440.57 KB)
|
11th International Respiratory Syncytial Virus Symposium |
| Title | Topic | Year | Link | Document | Notes |
|---|---|---|---|---|---|
| Update on Novavax NanoFlu™ vaccine and COVID-19-NanoFlu Combination Vaccine development | COVID-19 | 2021 | Document
|
Presentation by Vivek Shinde, MD, MPH at the World Vaccine Congress Europe 2021. |
|
| Novavax Program Update for ISV | COVID-19 | 2021 | Document
|
Dr. Gregory Glenn's COVID-19 presentation for the International Society for Vaccines (ISV) May 2021. |
|
| Novavax COVID-19 program update | COVID-19 | 2021 | Document
NVAX-WVC2021-GregGlenn-FINAL.pdf
(9.13 MB)
|
Dr. Gregory Glenn's presentation at the World Vaccine Congress Washington 2021. |
|
| Efficacy Data Updates from Novavax’ Protein-based Vaccine Candidate | COVID-19 | 2021 | Document
20210202-NYAS-Novavax-Final.pdf
(21.21 MB)
|
Dr. Gregory Glenn's presentation at the New York Academy of Science event, The Quest for a COVID-19 Vaccine. New York Academy of Sciences symposium, “The Quest for a COVID-19 Vaccine”, Feb 2-3, 2021 |
|
| NVX-CoV2373 Vaccine Candidate | COVID-19 | 2020 | Document
NovavaxPresentationforACIP.pdf
(1.14 MB)
|
Meeting Of The Advisory Committee On Immunization Practices (ACIP) |
|
| Recombinant nanoparticle COVID-19 vaccine: Platform technology for Emerging Infectious Diseases (EID) | COVID-19 | 2020 | Document
COVID19WVC20Oct20.pdf
(1.9 MB)
|
2020 World Vaccine Congress Europe |
|
| New Phase 2 NanoFlu data (features new cell-mediated immunity data) | Seasonal Influenza | 2020 | Document
|
World Vaccine Congress Washington 2020 |
|
| Recombinant nanoparticle COVID-19 vaccine: Platform technology for EID (Emerging Infectious Diseases) | COVID-19 | 2020 | Document
COVID-1.pdf
(1.44 MB)
|
World Vaccine Congress Washington 2020 |
|
| Phase 3 and beyond: Maternal RSV & older adult influence vaccine program | Respiratory Syncytial Virus | 2020 | Document
2020.10.01RSV-WVCWashington.pdf
(1.77 MB)
|
World Vaccine Congress Washington 2020 |
|
| NVX-CoV2373 COVID-19 Vaccine Candidate Phase 1/2, Part 1, Clinical Trial Results | COVID-19 | 2020 | Document
|
||
| Progress with the Full Length Recombinant Spike Protein Nanoparticle Vaccine | COVID-19 | 2020 | Document
20200721-ISV-Presentation.pdf
(1.23 MB)
|
2nd ISV COVID-19 Vaccines Virtual Congress |
|
| Learnings from a Phase 3 RSV Clinical Trial | Respiratory Syncytial Virus | 2020 | Document
20200623-NYASPresentation.pdf
(1.85 MB)
|
New York Academy of Sciences: Innovations in Maternal, Neonatal, and Early Infancy Vaccines |
|
| NVX-CoV2373 Vaccine for COVID-19 | COVID-19 | 2020 | Document
2020-05-13WVCWebinarCOVID19v3.pdf
(1.82 MB)
|
World Vaccine Congress Webinar |
|
| NanoFlu Phase 3 Topline Data | Seasonal Influenza | 2020 | Document
toplineFluPhase3InvestorSlides-20200323.pdf
(729.97 KB)
|
||
| Induction of broadly cross-reactive immune responses against A(H3N2) viruses: results of a phase 2 trial of a novel recombinant hemagglutinin saponin-adjuvanted nanoparticle influenza vaccine (“NanoFlu”) | Seasonal Influenza | 2019 | Document
|
OPTIONS X for the Control of Influenza Conference |
|
| Towards an Improved Wild-type Sequence Based Hemagglutination Inhibition Assay (HAI) for the Evaluation of Influenza Vaccines: Challenges and New Developments | Seasonal Influenza | 2019 | Document
|
OPTIONS X for the Control of Influenza Conference |
|
| Safety of Third Trimester Immunization with a Respiratory Syncytial Virus (RSV) F Protein Vaccine and Protection of Infants over the First 180 Days of Life Against All-Cause Lower Respiratory Tract Infection | Respiratory Syncytial Virus | 2019 | Document
20190808-IDSOG-Presentation.pdf
(406.22 KB)
|
Infectious Diseases Society for Obstetrics and Gynecology |
|
| Phase 3 Prepare Study: Efficacy and Safety of an RSV Vaccine Administered to Pregnant Women for the Prevention of RSV Lower Respiratory Tract Infection in Infants | Respiratory Syncytial Virus | 2019 | Document
|
European Society for Pediatric Infectious Diseases |
|
| Phase 3 and beyond: The RSV F nanoparticle vaccine for infants via maternal immunization | Respiratory Syncytial Virus | 2019 | Document
2019.04.16-World_Vaccine_Congress.pdf
(1.65 MB)
|
World Vaccine Congress |
|
| Magnitude and Durability of Anti-F IgG and Palivizumab-Competitive Antibody (PCA) Responses One Year Following Immunization with RSV F NanoparticleV | Respiratory Syncytial Virus | 2018 | 11th International Respiratory Syncytial Virus Symposium |